Bluejay Therapeutics Stock
HealthTechLooking to sell Bluejay Therapeutics stock or options?
Bluejay Therapeutics develops therapeutic medicines aimed at providing curative treatments for serious viral and liver diseases. The company's approach targets the reduction of viral surface antigen monoclonal antibodies to restore adaptive immunity, with an initial focus on chronic hepatitis B (CHB) and chronic hepatitis D (CHD). This enables patients to enhance their immunity and recover from infections.
Investors Include:
RA Capital Management, HBM Healthcare Investments, InnoPinnacle, Frazier Lifesciences Acquisition, Wellington Management, RiverVest Venture Partners, Unicorn Capital Partners, T. Rowe Price Group, Octagon Capital Advisors, Novo Holdings, Arkin Bio Ventures, Synergenics, Yonjin Venture.